75. 52
HKD +0.08
+0.106%
- Market Cap
- Div Yield
30,069 Volume
75.44 HKD
Previous Close Want to track 2820 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
2820 closed yesterday higher at 75.52 HKD, an increase of 0.106% from Monday's close, completing a monthly increase of 10.2482% or 7.02 HKD. Over the past 12 months, 2820 stock gained 10.7331%.
2820 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
2820 Chart
Global X China Biotech ETF (2820) FAQ
What is the stock price today?
The current price is 75.52 HKD.
On which exchange is it traded?
Global X China Biotech ETF is listed on HKEX.
What is its stock symbol?
The ticker symbol is 2820.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Global X China Biotech ETF ever had a stock split?
No, there has never been a stock split.
Global X China Biotech ETF Profile
| HKEX Exchange | Hong Kong Country |
The Global X China Biotech ETF is an exchange-traded fund designed to provide exposure to Chinese companies operating within the biotechnology sector. Its primary function is to track the performance of the Solactive China Biotech Index, which includes Chinese businesses involved in the development and commercialization of biotechnological products and services. This ETF allows investors to gain insight into a burgeoning market characterized by significant innovation and growth potential, as China's biotechnology industry benefits from increased government support, growing healthcare demands, and a shift towards advanced medical solutions. The Global X China Biotech ETF impacts sectors such as pharmaceuticals, healthcare, and bioengineering by concentrating on companies specialized in gene editing, cellular therapy, and novel drug development. In the financial market, it plays a crucial role for investors seeking diversified exposure to cutting-edge Chinese biotech firms without the need to pick individual stocks, thereby offering a streamlined approach to participating in a major segment of China's rapidly expanding healthcare landscape.
Contact Information
Address: -
Phone: +82 (0)23 774 2222
